Subcutaneous immunoglobulin 16.5% for the treatment of
pediatric patients with primary antibody immunodeficiency

J 2023

Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency

GUPTA, Sudhir, Roger H. KOBAYASHI, Jiří LITZMAN, Laurel CHERWIN, Sonja HOELLER et. al.

Basic information

Original name

Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency

Authors

GUPTA, Sudhir (guarantor), Roger H. KOBAYASHI, Jiří LITZMAN (203 Czech Republic, belonging to the institution), Laurel CHERWIN, Sonja HOELLER and Huub KREUWEL

Edition

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, UNITED STATES, TAYLOR & FRANCIS LTD, 2023, 1744-666X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.400 in 2022

RIV identification code

RIV/00216224:14110/23:00130223

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/1744666X.2023.2144836

UT WoS

000884631100001

Keywords in English

Cutaquig; pediatric immunodeficiency; primary immunodeficiency disease; subcutaneous administration of immunoglobulin; subcutaneous immunoglobulin

Abstract

V originále

Plain Language Summary Human immunoglobulin (IG) is extracted from the plasma of donors as a sterile, purified blood product that is administered intravenously (via a vein [IVIG]) or subcutaneously (under the skin [SCIG]) and is used for a variety of disorders, including the prevention of infections in patients with primary immunodeficiency diseases (PIDDs) such as primary antibody immunodeficiencies. This review provides an overview of PIDD with a focus on SCIG treatment, including the properties and clinical trial results of a new SCIG 16.5% (Cutaquig, Octapharma) in pediatric patients. We also discuss the various benefits of SCIG including stable serum immunoglobulin G levels, high tolerability with fewer systemic side effects, and the flexibility of self-administration. The importance of early identification of PIDD, especially in pediatric patients, cannot be overstated to ensure prompt treatment. The safety, efficacy, and tolerability of SCIG 16.5% have been demonstrated in pediatric patients with PIDDs providing an additional therapeutic option in this vulnerable population. Introduction Human immunoglobulin (IG) administered intravenously (IVIG) or subcutaneously (SCIG) is used to prevent infections in patients with primary immunodeficiency diseases (PIDDs) such as primary antibody immunodeficiencies. Areas covered This review provides an overview of PIDD with a focus on SCIG treatment, including the properties and clinical trial results of a new SCIG 16.5% (Cutaquig, Octapharma) in pediatric patients. We also discuss the various benefits of SCIG including stable serum immunoglobulin G levels, high tolerability with fewer systemic side effects, and the flexibility of self-administration. Expert opinion Individualized treatment for PIDD in children is necessary given the different factors that affect administration of SCIG. Variables such as the dose, dosing interval, administration sites, and ancillary equipment can be adjusted to impact the long-term satisfaction with SCIG administration in pediatric patients. The successful work that has been conducted by both professional and patient organizations to increase awareness of PIDD, especially in pediatric patients, is substantial and ongoing. The importance of early diagnosis and treatment in the pediatric patient population cannot be overstated. The safety, efficacy, and tolerability of SCIG 16.5% have been demonstrated in pediatric patients with PIDDs providing an additional therapeutic option in this vulnerable population.

Citovat

GUPTA, Sudhir, Roger H. KOBAYASHI, Jiří LITZMAN, Laurel CHERWIN, Sonja HOELLER and Huub KREUWEL. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency. EXPERT REVIEW OF CLINICAL IMMUNOLOGY. UNITED STATES: TAYLOR & FRANCIS LTD, 2023, vol. 19, No 1, p. 7-17. ISSN 1744-666X. Available from: https://dx.doi.org/10.1080/1744666X.2023.2144836.

@article{2249411,
   author = {Gupta, Sudhir and Kobayashi, Roger H. and Litzman, Jiří and Cherwin, Laurel and Hoeller, Sonja and Kreuwel, Huub},
   article_location = {UNITED STATES},
   article_number = {1},
   doi = {http://dx.doi.org/10.1080/1744666X.2023.2144836},
   keywords = {Cutaquig; pediatric immunodeficiency; primary immunodeficiency disease; subcutaneous administration of immunoglobulin; subcutaneous immunoglobulin},
   language = {eng},
   issn = {1744-666X},
   journal = {EXPERT REVIEW OF CLINICAL IMMUNOLOGY},
   title = {Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency},
   url = {https://www.tandfonline.com/doi/full/10.1080/1744666X.2023.2144836},
   volume = {19},
   year = {2023}
}

TY  - JOUR
ID  - 2249411
AU  - Gupta, Sudhir - Kobayashi, Roger H. - Litzman, Jiří - Cherwin, Laurel - Hoeller, Sonja - Kreuwel, Huub
PY  - 2023
TI  - Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency
JF  - EXPERT REVIEW OF CLINICAL IMMUNOLOGY
VL  - 19
IS  - 1
SP  - 7-17
EP  - 7-17
PB  - TAYLOR & FRANCIS LTD
SN  - 1744666X
KW  - Cutaquig
KW  - pediatric immunodeficiency
KW  - primary immunodeficiency disease
KW  - subcutaneous administration of immunoglobulin
KW  - subcutaneous immunoglobulin
UR  - https://www.tandfonline.com/doi/full/10.1080/1744666X.2023.2144836
N2  - Plain Language Summary Human immunoglobulin (IG) is extracted from the plasma of donors as a sterile, purified blood product that is administered intravenously (via a vein [IVIG]) or subcutaneously (under the skin [SCIG]) and is used for a variety of disorders, including the prevention of infections in patients with primary immunodeficiency diseases (PIDDs) such as primary antibody immunodeficiencies. This review provides an overview of PIDD with a focus on SCIG treatment, including the properties and clinical trial results of a new SCIG 16.5% (Cutaquig, Octapharma) in pediatric patients. We also discuss the various benefits of SCIG including stable serum immunoglobulin G levels, high tolerability with fewer systemic side effects, and the flexibility of self-administration. The importance of early identification of PIDD, especially in pediatric patients, cannot be overstated to ensure prompt treatment. The safety, efficacy, and tolerability of SCIG 16.5% have been demonstrated in pediatric patients with PIDDs providing an additional therapeutic option in this vulnerable population. Introduction Human immunoglobulin (IG) administered intravenously (IVIG) or subcutaneously (SCIG) is used to prevent infections in patients with primary immunodeficiency diseases (PIDDs) such as primary antibody immunodeficiencies. Areas covered This review provides an overview of PIDD with a focus on SCIG treatment, including the properties and clinical trial results of a new SCIG 16.5% (Cutaquig, Octapharma) in pediatric patients. We also discuss the various benefits of SCIG including stable serum immunoglobulin G levels, high tolerability with fewer systemic side effects, and the flexibility of self-administration. Expert opinion Individualized treatment for PIDD in children is necessary given the different factors that affect administration of SCIG. Variables such as the dose, dosing interval, administration sites, and ancillary equipment can be adjusted to impact the long-term satisfaction with SCIG administration in pediatric patients. The successful work that has been conducted by both professional and patient organizations to increase awareness of PIDD, especially in pediatric patients, is substantial and ongoing. The importance of early diagnosis and treatment in the pediatric patient population cannot be overstated. The safety, efficacy, and tolerability of SCIG 16.5% have been demonstrated in pediatric patients with PIDDs providing an additional therapeutic option in this vulnerable population.
ER  -

GUPTA, Sudhir, Roger H. KOBAYASHI, Jiří LITZMAN, Laurel CHERWIN, Sonja HOELLER and Huub KREUWEL. Subcutaneous immunoglobulin 16.5\%{} for the treatment of pediatric patients with primary antibody immunodeficiency. \textit{EXPERT REVIEW OF CLINICAL IMMUNOLOGY}. UNITED STATES: TAYLOR \&{} FRANCIS LTD, 2023, vol.~19, No~1, p.~7-17. ISSN~1744-666X. Available from: https://dx.doi.org/10.1080/1744666X.2023.2144836.

Detailed Information on Publication Record